News

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.

The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.

An analysis of data from the Veterans Health Administration provides insight into disparities in the rates of endoscopy or colonoscopy among patients with iron deficiency anemia or hematochezia.

The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

Nationwide data from Korea suggest abstinence from alcohol led to lower risks of clinical outcomes among patients with newly diagnosed open-angle glaucoma.

Results of the COMPACT study detail persistence rates, QoL data, and efficacy of biosimilar etanercept among patients in real-world settings.

The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.

Data from a 24-week, prospective trial conducted at a hospital in China provide insight into the effects of roxadustat on iron metabolism relative to use of ESAs in patients using peritoneal dialysis.

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.

Although respondents agreed on the relevance of the gut microbiota in IBD, attitudes toward the clinical application of microbiome-based therapies varied.

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

A new analysis of Google search results provides perspective into the readability and quality of educational materials available online related to iron deficiency anemia.

Outlook Therapeutics plans to resubmit the BLA for ophthalmic bevacizumab by the end of 2024, pending the successful completion of a required additional trial.

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.